ACRO funds research into CROs’ role in drug development

By Nick Taylor

- Last updated on GMT

Related tags Drug development Clinical trial Research Innovation Acro

ACRO is aiming to increase recognition and analysis of the value CROs bring to drug development, spanning their role as strategic partners throughout the process, by funding academic research.

Contract research organisations (CRO) are playing an increasingly pivotal role in drug development but recognition of this is limited, John Lewis, vice president of public affairs at the Association of Clinical Research Organisations (ACRO) told Outsourcing-Pharma.

To remedy this situation ACRO is aiming to build a body of academic research looking at the role CROs play in drug development. A key component of this effort was implemented this month when ACRO began funding the Global Healthcare Innovation Management Center (GHIMC).

Lewis explained that the GHIMC, a part of Fordham University, New York, US, is researching a number of topics in the field of healthcare innovation, one of which is the role of outsourcing in drug development.

Improving drug development

ACRO hopes the project will promote understanding of the role of CROs and the value they bring, as well as offering broader insight into how to improve drug development. The broad scope of the research project means this could cover topics beyond outsourcing, added Lewis.

Research around how to best manage these evolving development models is critically important to the future of the biopharmaceutical industry and ACRO is pleased to be among the founding members of this valuable research centre​”, said Doug Peddicord, executive director of ACRO.

Peddicord has taken a seat on the advisory board of the research programme. Preliminary work is expected to be shown in the summer, according to Lewis. In addition, ACRO is looking for academics in Europe and the US who operate in the research field.

The scope of the research project extends beyond drug development, into areas such as biotech clusters and healthcare delivery systems. Lewis added that additional funding sources are being sought within the pharma and insurance sectors.

Related news

Show more

Related products

show more

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

Related suppliers

Follow us


View more